Consistent improvements in liver histology across subgroups in a post hoc analysis of the SYNERGY-NASH trial with tirzepatide
In participants with metabolic dysfunction-associated steatohepatitis (MASH), tirzepatide demonstrated superiority to placebo for resolution of MASH without worsening of fibrosis, but the extent of MASH resolution across clinically relevant subgroups was not reported. In these <i>post hoc</i> analyses, we show that tirzepatide was consistently associated with improved MASH resolution without worsening of fibrosis across subgroups defined by demographics, histology, serum biomarkers, and imaging tests. These data support further investigation of tirzepatide in larger studies of participants with MASH including representation from diverse populations.
Authors
- Yuanyuan Tang (ORCID: https://orcid.org/0000-0001-6873-9467)
- Masato Yoneda (ORCID: https://orcid.org/0000-0001-7815-549X)
- Raj Vuppalanchi (ORCID: https://orcid.org/0000-0003-0637-1577)
- Elisabetta Bugianesi (ORCID: https://orcid.org/0000-0002-0502-4381)
- Axel Haupt (ORCID: https://orcid.org/0000-0003-4502-0470)
- Mathijs C. Bunck (ORCID: https://orcid.org/0000-0002-2862-6705)
- Rohit Seth Loomba (ORCID: https://orcid.org/0000-0002-4845-9991)
- Mark L. Hartman (ORCID: https://orcid.org/0000-0003-2396-7356)
- Bram Brouwers (ORCID: https://orcid.org/0000-0002-3676-5051)
- Jérôme Boursier (ORCID: https://orcid.org/0000-0002-7282-1436)
- Arun Jayant Sanyal (ORCID: https://orcid.org/0000-0001-8682-5748)
- Eric Lawitz (ORCID: https://orcid.org/0000-0002-4234-224X)
Institutions
- The University of Texas at San Antonio Health Science Center (US)
- Eli Lilly (United States) (US)
- Virginia Commonwealth University (US)
- University of California San Diego (US)
- University of California San Diego Medical Center (US)
- Texas Liver Institute (US)
- Indiana University School of Medicine
- Université d'Angers (FR)
- University of Turin (IT)
- Indiana University – Purdue University Indianapolis (US)
- Yokohama City University (JP)
Publication Details
- Journal
- JHEP Reports
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1016/j.jhepr.2025.101472
- Citations
- 3
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.06
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Gilead Sciences
- Alnylam Pharmaceuticals
- Medpace
- Gilead Foundation
- Regeneron Pharmaceuticals
- Jazz Pharmaceuticals
- Arrowhead Pharmaceuticals
- Intercept Pharmaceuticals
- NGM Biopharmaceuticals
- Novo Nordisk
- Bausch Health
- Genentech
- Novartis Pharma
- Janssen Pharmaceuticals